Arthur M. Cohen & Associates LLC decreased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 8.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,663 shares of the company's stock after selling 1,401 shares during the quarter. Johnson & Johnson comprises about 0.8% of Arthur M. Cohen & Associates LLC's holdings, making the stock its 25th largest position. Arthur M. Cohen & Associates LLC's holdings in Johnson & Johnson were worth $2,767,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company's stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares during the period. State Street Corp grew its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company's stock valued at $23,178,548,000 after buying an additional 803,013 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Johnson & Johnson by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company's stock valued at $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Johnson & Johnson by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company's stock worth $3,344,295,000 after acquiring an additional 421,779 shares during the period. Finally, FMR LLC boosted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company's stock worth $3,323,883,000 after acquiring an additional 3,229,032 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.
Get Johnson & Johnson alerts:Analysts Set New Price Targets
A number of equities analysts have weighed in on the stock. Atlantic Securities increased their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a "neutral" rating in a research note on Wednesday, January 25th. Guggenheim started coverage on Johnson & Johnson in a research report on Tuesday, February 28th. They issued a "neutral" rating and a $161.00 target price on the stock. Morgan Stanley upped their price target on Johnson & Johnson from $176.00 to $180.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 25th. SVB Leerink reduced their price objective on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a research note on Friday, January 20th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They set a "strong-buy" rating for the company. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $174.73.
Johnson & Johnson Trading Up 1.0 %
JNJ opened at $152.65 on Friday. The firm's 50 day moving average is $159.76 and its 200-day moving average is $167.55. Johnson & Johnson has a 52-week low of $150.11 and a 52-week high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $397.54 billion, a P/E ratio of 22.65, a P/E/G ratio of 2.60 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. The firm's quarterly revenue was down 4.4% on a year-over-year basis. Analysts expect that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date was Friday, February 17th. Johnson & Johnson's dividend payout ratio is currently 67.06%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company's stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company's stock, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.35% of the stock is owned by insiders.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 5 Best Dividend Capture Stocks
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.